Resverlogix Corp. (TSE:RVX – Get Free Report) reached a new 52-week low during trading on Wednesday . The company traded as low as C$0.04 and last traded at C$0.04, with a volume of 27000 shares trading hands. The stock had previously closed at C$0.05.
Resverlogix Trading Down 11.1 %
The company has a market capitalization of C$7.92 million, a price-to-earnings ratio of -1.98 and a beta of 0.71. The business’s 50 day simple moving average is C$0.05 and its 200 day simple moving average is C$0.06. The company has a debt-to-equity ratio of -10.95, a current ratio of 0.13 and a quick ratio of 0.04.
About Resverlogix
Resverlogix Corp clinical-stage biotechnology company. The company is developing an advanced epigenetic drug called apabetalone for the treatment of patients with cardiovascular disease, diabetes mellitus, chronic kidney disease, peripheral artery disease, orphan diseases, and neurodegenerative diseases.
Further Reading
- Five stocks we like better than Resverlogix
- Are These Liquid Natural Gas Stocks Ready For An Upside Bounce?
- Corporate Crawl: Where Business Trips Turn Into Party Nights
- How to Capture the Benefits of Dividend Increases
- CrowdStrike’s Growth Remains Strong—Buy While It’s Down
- How to Use Stock Screeners to Find Stocks
- Is Advanced Micro Devices Stock Slide Over?
Receive News & Ratings for Resverlogix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Resverlogix and related companies with MarketBeat.com's FREE daily email newsletter.
